The effectiveness of metabiotics in the treatment of acute respiratory diseases

Abstract

This article discusses the relevance and prospects of using metabiotics and targeted metabiotics in the complex therapy of acute respiratory diseases. The metabiotics (postbiotics) include bacterial metabolites and/or signaling molecules with a known chemical structure that optimize the composition and functions of the indigenous microbiota, including improving human immunity and metabolism. Bacterial metabolites of Bacillus subtilis SA44 and Lactobacillus rhamnosus CRL1505 strains demonstrate high efficiency in the treatment of patients with respiratory diseases. It is important to use targeted metabiotics, i.e. metabiotics that contribute to the restoration and maintenance of the microbiota of the respiratory organs and human immunity. Targeted metabiotics, as a rule, contain not only bacterial metabolites, but also additional substances with positive effects aimed at optimizing the functioning of a particular organ or system. An example of a targeted metabiotic for the treatment of acute respiratory diseases is a three-component Biocomplete® Bronchobiotic complex, which includes inactivated bacteria of the species Lactobacillus rhamnosus CRL1505 (the metabiotic, is an antagonist of opportunistic and pathogenic microorganisms, promotes immunity), inulin (the prebiotic, serves as nutrition for the indigenous flora) and thyme extract (has expectorant, anti-inflammatory and bactericidal, antioxidant effect).